• 1
    Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 5616.
  • 2
    Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 334356.
  • 3
    Deininger M, O'Brien SG, Guilhot F et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009; 114: 462. Abstract 1126.
  • 4
    Vardiman JW, Melo J, Baccarani M. Chronic myelogenous leukemia, BCR/ABL1 positive. In: Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon, France: IARC Press, 2008; 327.
  • 5
    Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 180920.
  • 6
    Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 604151.
  • 7
    Muller MC, Cross NC, Erben P et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 195763.
  • 8
    O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 51326.
  • 9
    Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 31925.
  • 10
    Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Investig 2011; 121: 396409.
  • 11
    Hamilton A, Helgason GV, Schemionek M et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 150110.
  • 12
    Mahon FX, Rea D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 102935.
  • 13
    Ross DM, Branford S, Seymour JF et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 171924.
  • 14
    Takahashi N, Kyo T, Maeda Y et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012; 97: 9036.
  • 15
    Ohyashiki K, Katagiri S, Tauchi T et al. Increased natural killer cells and decreased CD3+CD8 +CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 2012; 157: 2546.
  • 16
    Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 74563.
  • 17
    Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 97981.
  • 18
    Rousselot P, Huguet F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 5860.
  • 19
    Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 594458.
  • 20
    Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. NK cells and immune “memory”. J Immunol 2011; 186: 18917.
  • 21
    Paust S, von AU. Natural killer cell memory. Nat Immunol 2011; 12: 5008.
  • 22
    Boissel N, Rea D, Tieng V et al. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 2006; 176: 510816.
  • 23
    Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 8504.
  • 24
    Bauer S, Corless CL, Heinrich MC et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003; 51: 2615.
  • 25
    Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Investig 2004; 114: 37988.
  • 26
    Menard C, Blay JY, Borg C et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009; 69: 35639.
  • 27
    Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia 2013; 27: 80312.
  • 28
    Veneri D, Tecchio C, De MG et al. Long-term persistence of molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia. Blood Transfus 2012; 10: 2334.
  • 29
    Kreutzman A, Rohon P, Faber E et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 2011; 6: e23022.
  • 30
    Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8 +  T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892900.
  • 31
    Kanodia S, Wieder E, Lu S et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS ONE 2010; 5: e11770.
  • 32
    Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996; 87: 247685.
  • 33
    Mustjoki S, Ekblom M, Arstila TP et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398405.
  • 34
    Kim DH, Kamel-Reid S, Chang H et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 1359.
  • 35
    Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 44156.
  • 36
    Fraser CK, Blake SJ, Diener KR et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4 +  and CD8 +  T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37: 25665.
  • 37
    Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 38798.
  • 38
    Salih J, Hilpert J, Placke T et al. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 211928.
  • 39
    Chen CI, Koschmieder S, Kerstiens L et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012; 26: 46574.
  • 40
    Pierson BA, Miller JS. CD56 + bright and CD56 + dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88: 227987.
  • 41
    Fujimiya Y, Bakke A, Chang WC et al. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1. Int J Cancer 1986; 37: 63949.
  • 42
    Ng KP, Hillmer AM, Chuah CT et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 5218.
  • 43
    Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients. Br J Haematol 2013; 160: 26971.